Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) EBT Margin (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed EBT Margin for 7 consecutive years, with 18.2% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 3930.0% to 18.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 29.74% through Dec 2025, up 22890.0% year-over-year, with the annual reading at 29.74% for FY2025, 22890.0% up from the prior year.
  • EBT Margin for Q4 2025 was 18.2% at Madrigal Pharmaceuticals, up from 38.68% in the prior quarter.
  • The five-year high for EBT Margin was 18.2% in Q4 2025, with the low at 1038.2% in Q2 2024.